Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Fuji
Deloitte
Harvard Business School
Cerilliant
Citi
Covington
Argus Health
Teva

Generated: May 21, 2018

DrugPatentWatch Database Preview

Valeant Intl Company Profile

« Back to Dashboard

What is the competitive landscape for VALEANT INTL, and when can generic versions of VALEANT INTL drugs launch?

VALEANT INTL has thirteen approved drugs.

There are three US patents protecting VALEANT INTL drugs.

There are twenty patent family members on VALEANT INTL drugs in eleven countries and thirty supplementary protection certificates in twelve countries.

Summary for Valeant Intl
International Patents:20
US Patents:3
Tradenames:11
Ingredients:7
NDAs:13

Drugs and US Patents for Valeant Intl

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Intl CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-006 Feb 6, 2003 AB RX Yes Yes 6,923,984 ➤ Try a Free Trial Y ➤ Try a Free Trial
Valeant Intl CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-005 Feb 6, 2003 AB RX Yes No 7,108,866 ➤ Try a Free Trial Y ➤ Try a Free Trial
Valeant Intl CARDIZEM CD diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020062-003 Dec 27, 1991 AB3 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Valeant Intl VASERETIC enalapril maleate; hydrochlorothiazide TABLET;ORAL 019221-001 Oct 31, 1986 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Valeant Intl

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Intl CARDIZEM diltiazem hydrochloride TABLET;ORAL 018602-001 Nov 5, 1982 3,562,257 ➤ Try a Free Trial
Valeant Intl RETIN-A MICRO tretinoin GEL;TOPICAL 020475-002 May 10, 2002 5,955,109 ➤ Try a Free Trial
Valeant Intl CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-004 Feb 6, 2003 5,529,791 ➤ Try a Free Trial
Valeant Intl CARDIZEM CD diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020062-004 Dec 27, 1991 5,439,689 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for VALEANT INTL drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Tablets 150 mg and 300 mg ➤ Subscribe 2004-09-21
➤ Subscribe Extended-release Tablets 420 mg ➤ Subscribe 2005-04-25
➤ Subscribe Gel 0.04% ➤ Subscribe 2010-12-20
➤ Subscribe Extended-release Tablets 120 mg, 180 mg, 240 mg, 300 mg and 360 mg ➤ Subscribe 2005-08-30
➤ Subscribe Gel 0.1% ➤ Subscribe 2010-07-08

Non-Orange Book US Patents for Valeant Intl

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,143,327 Delayed release coated tablet of bupropion hydrochloride ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Valeant Intl Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2017000109 Germany ➤ Try a Free Trial PRODUCT NAME: NALTREXON ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE NALTREXONHYDROCHLORID, UND BUPROPION ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE BUPROPIONHYDROCHLORID; REGISTRATION NO/DATE: EU/1/14/988 20150326
1304992/01 Switzerland ➤ Try a Free Trial PRODUCT NAME: CLINDAMYCINI PHOSPHAS ET TRETINOINUM; REGISTRATION NO/DATE: SWISSMEDIC 62513 28.03.2014
C/GB01/014 United Kingdom ➤ Try a Free Trial PRODUCT NAME: ALITRETINOIN; REGISTERED: UK EU/1/00/149/001 20001018
2013 00053 Denmark ➤ Try a Free Trial PRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Fuji
Medtronic
Queensland Health
Cerilliant
Teva
Johnson and Johnson
QuintilesIMS
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.